Mechanisms behind the LncRNAs-mediated regulation of paclitaxel (PTX) resistance in human malignancies

被引：0

作者：

Alkhathami, Ali G. ^{[1
]}

Pallathadka, Harikumar ^{[2
]}

Shah, Sejal ^{[3
]}

Ganesan, Subbulakshmi ^{[4
]}

Sharma, Abhishek ^{[5
]}

Devi, Seema ^{[6
]}

Mustafa, Yasser Fakri ^{[7
]}

Alasheqi, Mohammed Qasim ^{[8
]}

Kadhim, Abed J. ^{[9
]}

Zwamel, Ahmed Hussein ^{[10
,11
,12
]}

机构：

[1] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia

[2] Manipur Int Univ, Imphal, Manipur, India

[3] Marwadi Univ, Res Ctr, Fac Engn & Technol, Dept Bioinformat, Rajkot 360003, Gujarat, India

[4] JAIN Deemed Univ, Sch Sci, Dept Chem & Biochem, Bangalore, Karnataka, India

[5] Nims Univ Rajasthan, Natl Inst Med Sci, Dept Med, Jaipur, India

[6] Chandigarh Pharm Coll, Chandigarh Grp Coll, Mohali 140307, Punjab, India

[7] Univ Mosul, Coll Pharm, Dept Pharmaceut Chem, Mosul 41001, Iraq

[8] Natl Univ Sci & Technol, Coll Pharm, Dhi Qar, Iraq

[9] AL Nisour Univ Coll, Dept Med Engn, Baghdad, Iraq

[10] Islamic Univ, Coll Med & Tech, Najaf, Iraq

[11] Islamic Univ Al Diwaniyah, Med Lab Tech Coll, Al Diwaniyah, Iraq

[12] Islamic Univ Babylon, Med Lab Tech Coll, Babylon, Iraq

来源：

EXPERIMENTAL CELL RESEARCH | 2025年 / 445卷 / 02期

关键词：

LncRNA; Paclitaxel; Resistance; Cancer; Mechanism; LONG NONCODING RNAS; OVARIAN-CANCER; BREAST-CANCER; PROMOTES; EXPRESSION; CELLS; PROLIFERATION; BEVACIZUMAB; CARBOPLATIN; APOPTOSIS;

D O I：

10.1016/j.yexcr.2025.114434

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Paclitaxel (PTX) is extensively used to treat various cancers, including those of the breast, ovary, lung, esophagus, stomach, pancreas, and neck. However, despite its effectiveness in clinical settings, patients often experience cancer recurrence due to the emergence of resistance to PTX. The mechanisms underlying this resistance in cancer cells exposed to PTX involve modifications in beta-tubulin, the primary target molecule associated with mitosis, the activation of pathways that facilitate drug efflux, and the dysregulation of apoptosis-related proteins. Long non-coding RNAs (lncRNAs), which are RNA molecules exceeding 200 nucleotides in length and lacking protein-coding capabilities, play various regulatory roles in cellular functions. A growing body of evidence underscores the role of lncRNAs in cancer progression and their involvement in PTX resistance across different cancer types. As a result, lncRNAs have been identified as promising therapeutic targets for overcoming drug resistance in cancer therapies. This review aims to provide an overview of the current knowledge regarding lncRNAs and their contributions to resistance mechanisms to promote further research in this field. A summary of key lncRNAs and their related pathways associated with PTX resistance will be presented.

引用

页数：11

共 131 条

[1] Rizzo A., Santoni M., Mollica V., Logullo F., Rosellini M., Marchetti A., Faloppi L., Et al., Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study, Expet Opin. Drug Metabol. Toxicol., 17, 12, pp. 1455-1466, (2021)
[2] Mohapatra S., Pioppini C., Ozpolat B., Calin G.A., Non-coding RNAs regulation of macrophage polarization in cancer, Mol. Cancer, 20, pp. 1-15, (2021)
[3] Ashrafizaveh S., Ashrafizadeh M., Zarrabi A., Husmandi K., Zabolian A., Shahinozzaman M., Aref A.R., Et al., Long non-coding RNAs in the doxorubicin resistance of cancer cells, Cancer Lett., 508, pp. 104-114, (2021)
[4] Rizzo A., Santoni M., Mollica V., Fiorentino M., Brandi G., Massari F., Microbiota and prostate cancer, Semin. Cancer Biol., 86, pp. 1058-1065, (2022)
[5] Entezari M., Ghanbarirad M., Taheriazam A., Sadrkhanloo M., Zabolian A., Goharrizi M.A.S.B., Hushmandi K., Et al., Long non-coding RNAs and exosomal lncRNAs: potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling, Biomed. Pharmacother., 150, (2022)
[6] Chen H., Zhang M., Deng Y., Long noncoding RNAs in taxane resistance of breast cancer, Int. J. Mol. Sci., 24, 15, (2023)
[7] Ding Q., Lin F., Huang Z., Li Y., Cai S., Chen X., Liu H., Et al., Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment, Sci. Rep., 14, 1, (2024)
[8] Ding Y., Zhen Z., Nisar M.A., Ali F., Din R.U., Khan M., Mughal T.A., Et al., Sesquiterpene lactones attenuate paclitaxel resistance via inhibiting MALAT1/STAT3/FUT4 Axis and P-glycoprotein transporters in lung cancer cells, Front. Pharmacol., 13, (2022)
[9] Ghafouri-Fard S., Shoorei H., Abak A., Abbas Raza S.H., Pichler M., Taheri M., Role of non-coding RNAs in modulating the response of cancer cells to paclitaxel treatment, Biomed. Pharmacother., 134, (2021)
[10] Ghafouri-Fard S., Shoorei H., Abak A., Raza S.H.A., Pichler M., Taheri M., Role of non-coding RNAs in modulating the response of cancer cells to paclitaxel treatment, Biomed. Pharmacother., 134, (2021)

← 1 2 3 4 5 6 7 8 9 10 →